Production (Stage)
Stoke Therapeutics, Inc.
STOK
$9.43
$0.252.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 527.99% | 61.12% | -7.69% | 16.18% | -16.98% |
| Total Depreciation and Amortization | -15.28% | -15.71% | -15.23% | -10.31% | -5.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.53% | 5.78% | 7.49% | 7.39% | -8.24% |
| Change in Net Operating Assets | 347.56% | -2,205.83% | -823.93% | -102.80% | 20.18% |
| Cash from Operations | 636.62% | -12.32% | -25.22% | 19.83% | -15.03% |
| Capital Expenditure | -1,166.67% | 81.66% | 73.11% | 94.52% | 92.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.84% | -94.26% | -299.34% | -462.92% | -81.22% |
| Cash from Investing | 36.48% | -94.46% | -305.27% | -476.08% | -81.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -19.98% | -92.26% | 1,351.78% | 251,254.17% | -96.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -19.98% | -92.26% | 1,351.78% | 251,254.17% | -96.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,241.69% | -1,588.46% | -1,986.41% | 765.49% | -116.75% |